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Wilms tumor (WT), also known as nephroblastoma, is a cancer of the kidneys that is diagnosed 
predominantly in young children. Although five year survival rates are consistently above 90%, the 
disease and its treatment may continue to adversely affect the quality of life among survivors. Most 
notably, end-stage renal disease (ESRD), the incidence of which varies considerably across patient 
subgroups (0.6-90%), is one of the most serious late-effects due to its high mortality rate and 
cardiovascular damage, as well as impaired cognitive development and growth retardation 
associated with long-term dialysis. 
Pediatric patients with ESRD have high priority for renal transplantation, but the procedure is 
typically delayed for one to two years following treatment for WT because of deaths and tumor 
recurrences reported in early studies. Yet, in light of the advances in preventing and treating acute 
graft rejection and in dealing with immunosuppression, Dr. Yevgeny Grigoriev and several 
colleagues from the Public Health Sciences Division recently investigated the timing of kidney 
transplantation in relation to WT treatment in order to determine whether the recommended waiting 
time remains appropriate. 
Specifically, Grigoriev examined time-to-transplant and survival outcomes in 173 children enrolled in 
the National Wilms Tumor Study who received kidney replacement therapy (dialysis or renal 
transplant) for ERSD and compared their outcomes to a random age-matched population sample 
with ERSD from the U.S. Renal Data System. 
Fifty five patients with progressive bilateral Wilms tumor developed ESRD with the surgical removal 
of all kidney tissue and experienced high early mortality after chemotherapy which limited their 
opportunity for transplant (47% at 5 years) and survival (44% at 10 years). In contrast, 118 patients 
whose ESRD resulted from chronic kidney disease that developed from a variety of causes, had 
good opportunity for transplant (66% within 2 years; 77% at 5 years) and survival outcomes no 
worse than the population controls (73% at 10 years). However, once a transplant had been 
performed, the differences in outcomes between groups were markedly reduced. The authors also 
noted that minority children had twice the median time to transplant as non-Hispanic white patients 
(3.1 years vs. 1.5 years) and higher mortality rates, consistent with population trends.  
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Relative to patients who received a transplant more than two years after WT treatment, the hazard 
ratios for death following transplant were 0.9 (95% Confidence Interval (CI): 0.3-3.3) and 0.6 (95% 
CI: 0.1-2.6) for transplants occurring less than one year and one to two years after chemotherapy, 
respectively. 
Given that none of the study results suggested a markedly adverse prognosis associated with early 
transplantation, and because of the dramatic improvement in outlook following kidney 
transplantation, the authors believe that re-evaluation of the current recommendation for a two year 
delay in transplant following treatment for Wilms tumor may be warranted. 
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Figure. A) Cumulative incidence curves 
showing proportions of patients who received 
an initial transplant by time since onset of 
end-stage renal disease (ESRD); B) Survival 
curves (proportions of surviving patients) by 
time since onset of ESRD for four groups. 
NWTS-CKD and NWTS-PBWT refer to National 
Wilms Tumor Study (NWTS) patients whose 
ESRD was due to progressive bilateral Wilms 
tumor (PBWT) and chronic kidney disease 
(CKD), respectively. USRD-PBWT and USRD-
CKD refer to stratified samples of USRDS 
(United States Renal Data System) patients 
that were frequency-matched on age at ESRD 
onset to the corresponding NWTS 
populations. 
